GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models

Glucagon-like peptide 1 receptor (GLP-1R) agonists decrease body weight and improve glycemic control in obesity and diabetes. Patient compliance and maximal efficacy of GLP-1 therapeutics are limited by adverse side effects, including nausea and emesis. In three different species (i.e., mice, rats,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2021-11, Vol.70 (11), p.2545-2553
Hauptverfasser:	Borner, Tito, Geisler, Caroline E, Fortin, Samantha M, Cosgrove, Richard, Alsina-Fernandez, Jorge, Dogra, Mridula, Doebley, Sarah, Sanchez-Navarro, Marcos J, Leon, Rosa M, Gaisinsky, Jane, White, Arianna, Bamezai, Ankur, Ghidewon, Misgana Y, Grill, Harvey J, Crist, Richard C, Reiner, Benjamin C, Ai, Minrong, Samms, Ricardo J, De Jonghe, Bart C, Hayes, Matthew R
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Animals Area postrema Body weight Body Weight - drug effects Body weight loss Diabetes Diabetes mellitus Feeding Behavior Food intake GIP protein GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Glucose tolerance Hindbrain Male Mice Mice, Inbred C57BL Nausea Nausea - chemically induced Nausea - drug therapy Obesity Obesity Studies Phenotypes Rats Rats, Sprague-Dawley Receptors, Gastrointestinal Hormone - agonists Shrews Solitary tract nucleus Vomiting Weight control γ-Aminobutyric acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!